MedStar Health Treats First COVID-19 Patient With Lenzilumab

I am proud to share that MedStar Washington Hospital Center treated its first COVID-19 patient with study drug lenzilumab. MedStar Health is one of 18 sites participating in this Phase 3, multi-center clinical trial to assess whether the use of lenzilumab can alleviate the immune-mediated cytokine release syndrome and reduce the time to recovery in hospitalized patients with severe or critical COVID-19 pneumonia. Humanigen,a clinical stage biopharmaceutical company,announced the news this week onYahoo! Finance

This is just one of many active studies at MedStar Health that is helping us to advance health for today and the future. Learn more about our active clinical trials here.
 
Congratulations to MedStar Health Principal Investigator, Dr. Seife Yohannes and the study team for this remarkable milestone! 
 

Comments

Popular posts from this blog

"Betsey, Lucy, and Anarcha: Recognition and Remembrance" with MHRI

World Medical Innovation Forum 2018

MedStar Health's Upcoming Advertising Campaign!